Eli Lilly and Company.
American pharmaceutical company
- Reports this week
- 49
- Active events
- 41
- Connections
- 839
What's happening
Active this week
-
ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Some support1 report
-
The FDA approved Olumiant for pediatric indications on September 1, 2026.Some support1 report
-
Eli Lilly and Company filed a disclosure with the Securities and Exchange Commission on June 15, 2026.Well supported21 reports1 development inside
-
Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Some support1 report
-
Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.Well supported16 reports1 development inside
-
MarketBeat listed Abbott, Eli Lilly, Pfizer, Gilead, AbbVie, and McKesson as stocks to watch on June 7, 2026.Some support7 reports
-
Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.Well supported6 reports3 developments inside
-
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Well supported10 reports7 developments inside
-
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Well supported16 reports1 development inside
-
Berenberg Bank raised a price target and gave a 'hold' rating on Eli Lilly and Company, alongside filing required reports with the SEC.Well supported3 reports
-
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Well supported29 reports10 developments inside
-
Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Well supported3 reports
-
Eli Lilly and Company sponsored a symposium hosted by the Breast Cancer Alliance.Some support1 report
-
Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Some support1 report1 development inside
-
Eli Lilly and Company received FDA approval for Onswik, a new treatment for Type 2 diabetes.Some support1 report
-
The FDA has cleared two P-tau217 blood tests for use and is collaborating on blood-based biomarker test development.Some support1 report
-
FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.Well supported4 reports1 development inside
-
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Well supported27 reports6 developments inside
-
Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.Some support1 report
-
The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.Some support1 report
-
David Ricks assessed the competitive standing of Indiana, noting needed improvements regarding how city issues like public safety impact the state's image, which is crucial for companies like Eli Lilly.Some support1 report
-
Langone's portfolio ranking favors Eli Lilly over Home Depot.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
European rearmament pledges are driving investment into defense funds, coinciding with FED decisions rattling global markets and stock names.Some support1 report
-
Interactive Brokers' shares outperformed the S&P 500 on September 3, 2025, while Eli Lilly's shares faced pressure and underperformed.Some support3 reports
-
Pfizer and Eli Lilly are being discussed as potential dividend investment targets.Some support2 reports
-
Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.Some support1 report
-
Fifth Third Bancorp lifted its holdings in Eli Lilly and Company, while Norges Bank purchased a new position in the company's shares. These actions required filings with the SEC.Some support1 report
-
Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.Some support1 report
-
Analysis compares Vanguard's VUG and Invesco's QQQM, noting VUG's lower expense ratio and QQQM's lack of Eli Lilly exposure.Some support1 report
-
Eli Lilly and Company is planning a future manufacturing site in Houston, Texas, involving a $6.5 billion investment and network expansion.Well supported4 reports1 development inside
-
Eli Lilly and Company is building a major manufacturing facility in Harris County, Texas.Some support1 report
-
Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Some support8 reports
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
-
Eli Lilly and Company entered a strategic partnership with Twist Bioscience Corporation regarding data provision and services.Some support3 reports
-
Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.Some support1 report
-
OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.Some support2 reports
-
Novo announced a strategic partnership with Anthropic, Mike Doustdar was installed as CEO, and Eli Lilly gained market share in obesity care.Some support1 report
-
Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.Some support1 report1 development inside
-
Eli Lilly and Company was involved in a business event in Indianapolis where Mike Doustdar acknowledged the superiority of Lilly's pill.Some support3 reports
-
Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.Well supported4 reports
Earlier this month
-
Eli Lilly and Company and Wells Fargo are major players whose market performance is influenced by FED rate decisions and the banking sector's net interest margin.Some support1 report1 development inside
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Some support2 reports3 developments inside
-
The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.Some support2 reports
-
Eli Lilly's obesity and diabetes drug pipeline is cited as a driver of market growth.Some support1 report1 development inside
-
Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.Some support1 report
-
On August 14, 2025, financial institutions inquired about market trends, including type 2 diabetes acceleration, U.S. growth variability, and international growth drivers.Some support3 reports2 developments inside
-
Novo Nordisk expanded its pediatric label franchise on September 15, 2026.Some support1 report
-
A group called The Studio Players was founded in 2013 due to a gap in the scene, involving Eli Lilly and Company.Some support1 report
-
Scott Galloway critiques SpaceX's IPO valuation and recommends Eli Lilly, noting both companies are involved in the GLP-1 drug market.Well supported6 reports2 developments inside
-
MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.Some support1 report
-
Bridgewater Associates increased its Eli Lilly share position, while ARK Invest held a significant stake in Eli Lilly and added to its Nvidia holdings.Some support1 report
-
Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.Some support1 report
-
An incident occurred at the home base of Eli Lilly and Company on September 15, 2026.Some support1 report
-
The Food and Drug Administration approved Mounjaro, a drug developed by Eli Lilly and Company.Well supported8 reports
-
Eli Lilly and Company presented portfolio data and hosted a major medical conference in Milan, Italy.Some support1 report
-
Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.Some support1 report
-
Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Some support2 reports
-
Market pressure due to cost trends is affecting major companies including UnitedHealth Group, Molina Healthcare, Abbott Laboratories, and Eli Lilly, as reported on Investopedia.Some support1 report6 developments inside
-
GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Eli Lilly and Company this week
News at the entities that move Eli Lilly and Company most-
Johnson & Johnson OperationalP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Eli Lilly and Company
-
Indiana StructuralA new agricultural strategy initiative in Indiana was developed in partnership with the Indiana Economic Development Association and supported by Duke Energy.Moves Eli Lilly and Company
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Eli Lilly and Company
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Eli Lilly and Company
-
Federal Trade Commission StructuralTrump is accused of destroying the structure involving the Department of Education, the Federal Trade Commission, and the East Wing.Moves Eli Lilly and Company
-
China StructuralThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Eli Lilly and Company
Connections
The 40 strongest of 839, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
David Ricks Structural
David Ricks serves as the Chief Executive Officer of Eli Lilly and Company.
-
Johnson & Johnson Operational
The two pharmaceutical companies are engaged in direct, high-stakes market competition across various therapeutic and growth segments.
-
Viking Therapeutics Operational
Viking Therapeutics and Eli Lilly are direct competitors in the high-stakes market for GLP-1/GIP agonist drugs targeting obesity and weight management.
-
Nicholas Noyes Structural
Nicholas Noyes served as a vice president and director of Eli Lilly and Company.
-
Generation Park Structural
Eli Lilly is establishing a $6.5 billion manufacturing facility at Generation Park.
-
Indiana Structural
The relationship is a deep, mutually reliant partnership where Indiana provides the operational base and market, and Eli Lilly contributes major investment and product access.
-
Norges Bank Transactional
Norges Bank has repeatedly purchased new stakes and increased its holdings in Eli Lilly and Company.
-
FDA Structural
Eli Lilly's commercial viability and market access are formally dependent on the review, approval, and oversight of its products by the FDA.
Show all 40 connections
-
Verve Transactional
Eli Lilly and Company planned and initiated the acquisition of Verve Therapeutics for up to $1.3 billion.
-
Pfizer Operational
Pfizer and Eli Lilly are direct competitors vying for market share in high-growth pharmaceutical sectors, including GLP-1 weight loss and oncology.
-
Elanco Structural
Elanco was historically a division and subsidiary of Eli Lilly and Company.
-
Novo Nordisk Operational
The two companies are direct, high-stakes competitors in the global weight loss and diabetes drug markets, evidenced by market rivalry and active litigation.
-
Goochland County Shared context
Eli Lilly and Company has established a manufacturing facility within Goochland County.
-
CVS Health Operational
CVS and Eli Lilly engage in a dynamic operational relationship characterized by both market competition (formulary decisions) and strategic collaboration on patient access and distribution.
-
Federal Trade Commission Structural
The Federal Trade Commission is formally regulating Eli Lilly, including mandating divestment and investigating market practices.
-
SEC Structural
Eli Lilly and Company must comply with SEC regulations by filing mandatory reports on institutional holdings and stock transactions.
-
Securities and Exchange Commission Structural
Eli Lilly and Company is structurally required to file institutional reports, such as Form 13F, with the SEC.
-
China Structural
Eli Lilly relies on China for market access, national reimbursement, and drug sourcing.
-
AbbVie Operational
AbbVie and Eli Lilly are direct competitors in the global pharmaceutical market, vying for market share and therapeutic dominance.
-
Max Denning Structural
Max Denning serves as an associate vice president at Eli Lilly and Company.
-
European Medicines Agency Structural
The EMA's regulatory recommendations and approvals directly determine Eli Lilly's market access and financial performance in Europe.
-
Morgan Stanley Operational
Morgan Stanley provides financial research, investment ratings, and executes trades that influence the market valuation of Eli Lilly.
-
VOO Structural
Eli Lilly is a major component holding within the VOO ETF.
-
Goldman Sachs Operational
Goldman Sachs actively provides financial ratings, market analysis, and investor relations support for Eli Lilly and Company.
-
Donald Trump Operational
Trump utilizes his political influence, tariff threats, and market presence to drive strategic shifts, pricing discussions, and investment opportunities with Eli Lilly.
-
Amgen Operational
Both companies are direct competitors in advanced drug markets, specializing in GLP-1 agonists, obesity treatments, and Lp(a) reduction.
-
Bank of America Operational
Bank of America leverages its analyst coverage and research to actively influence market perception and stock performance of Eli Lilly.
-
Huntsville Structural
Eli Lilly is establishing a major manufacturing project and making a $6 billion investment in Huntsville.
-
Novartis Operational
The relationship is intense market competition, rooted in the historical divestiture of Novartis' Animal Health division to Lilly.
-
Health Resources and Services Administration Structural
Eli Lilly and Company is subject to compliance and oversight requirements and reporting mandates from the Health Resources and Services Administration.
-
Francisco Ramírez-Valle Structural
Francisco Ramírez-Valle serves as a Senior Vice President in the research division of Eli Lilly and Company.
-
Jim Cramer Operational
Jim Cramer actively tracks, recommends, and provides market support for Eli Lilly and Company's stock and pipeline.
-
AstraZeneca Operational
Eli Lilly and AstraZeneca are active competitors in the pharmaceutical market, vying for market share in oncology and obesity.
-
Merck KGaA Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Wang Li Structural
Wang Li serves as the head of the drug development center in China for Eli Lilly and Company.
-
Alabama Structural
Eli Lilly is committing $6 billion to establish a major operational presence with new manufacturing plants in Alabama.
-
Nvidia Operational
Nvidia and Eli Lilly are engaged in a high-stakes co-innovation partnership, utilizing Nvidia's AI infrastructure for Eli Lilly's advanced drug research and discovery initiatives.
-
Avantis Structural
Eli Lilly is a top investment holding within the Avantis ETF.
-
Charles River Laboratories Structural
Charles River Laboratories is functionally integrated into the Eli Lilly TuneLab platform.
-
Vidhya Structural
A was a past employee of B, establishing a historical structural link.
History
Events by the month they beganSeptember 2026
42 events- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.
- The FDA approved Olumiant for pediatric indications on September 1, 2026.
- Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Company sponsored a symposium hosted by the Breast Cancer Alliance.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly and Company received FDA approval for Onswik, a new treatment for Type 2 diabetes.
- The FDA has cleared two P-tau217 blood tests for use and is collaborating on blood-based biomarker test development.
- Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.
- The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.
- David Ricks assessed the competitive standing of Indiana, noting needed improvements regarding how city issues like public safety impact the state's image, which is crucial for companies like Eli Lilly.
- Langone's portfolio ranking favors Eli Lilly over Home Depot.
- European rearmament pledges are driving investment into defense funds, coinciding with FED decisions rattling global markets and stock names.
- Pfizer and Eli Lilly are being discussed as potential dividend investment targets.
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
- Fifth Third Bancorp lifted its holdings in Eli Lilly and Company, while Norges Bank purchased a new position in the company's shares. These actions required filings with the SEC.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Analysis compares Vanguard's VUG and Invesco's QQQM, noting VUG's lower expense ratio and QQQM's lack of Eli Lilly exposure.
- Eli Lilly and Company is planning a future manufacturing site in Houston, Texas, involving a $6.5 billion investment and network expansion.
- Eli Lilly and Company is building a major manufacturing facility in Harris County, Texas.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
- Eli Lilly and Company entered a strategic partnership with Twist Bioscience Corporation regarding data provision and services.
- Charles River Laboratories joined Eli Lilly’s TuneLab platform, while Trillium and LAL increased cartridge line capacity.
- OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.
- Novo announced a strategic partnership with Anthropic, Mike Doustdar was installed as CEO, and Eli Lilly gained market share in obesity care.
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
- Eli Lilly and Company and Wells Fargo are major players whose market performance is influenced by FED rate decisions and the banking sector's net interest margin.
- The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.
- Eli Lilly's obesity and diabetes drug pipeline is cited as a driver of market growth.
- Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
- A group called The Studio Players was founded in 2013 due to a gap in the scene, involving Eli Lilly and Company.
- MarketBeat listed UnitedHealth Group, Eli Lilly and Company, Moderna, Thermo Fisher Scientific Inc., Johnson & Johnson, and Illumina as stocks to watch.
- Bridgewater Associates increased its Eli Lilly share position, while ARK Invest held a significant stake in Eli Lilly and added to its Nvidia holdings.
- Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
- An incident occurred at the home base of Eli Lilly and Company on September 15, 2026.
- Eli Lilly and Company presented portfolio data and hosted a major medical conference in Milan, Italy.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.
August 2026
2 eventsJune 2026
16 events- Eli Lilly and Company filed a disclosure with the Securities and Exchange Commission on June 15, 2026.
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- MarketBeat listed Abbott, Eli Lilly, Pfizer, Gilead, AbbVie, and McKesson as stocks to watch on June 7, 2026.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Berenberg Bank raised a price target and gave a 'hold' rating on Eli Lilly and Company, alongside filing required reports with the SEC.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Interactive Brokers' shares outperformed the S&P 500 on September 3, 2025, while Eli Lilly's shares faced pressure and underperformed.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- On August 14, 2025, financial institutions inquired about market trends, including type 2 diabetes acceleration, U.S. growth variability, and international growth drivers.
- Scott Galloway critiques SpaceX's IPO valuation and recommends Eli Lilly, noting both companies are involved in the GLP-1 drug market.
- Market pressure due to cost trends is affecting major companies including UnitedHealth Group, Molina Healthcare, Abbott Laboratories, and Eli Lilly, as reported on Investopedia.